School of Pharmaceutical Sciences, Universiti Sains Malaysia

  • Qualification

    PhD (Pharmacy) (University of Sydney), MSc (USM), BSc (USM)

  • Senior Lecturer

    Discipline of Pharmaceutical Technology

  • President

    Malaysian Society of Pharmaceutical Technology

  • Co-chair

    Science Leadership Working Group, Young Scientists Network - Academy of Sciences Malaysia

  • Room

    J06 Room 122

  • Contact

    +604-6577888 Ext. 6813

  • Email

    thaigarp@usm.my

Author ID

Thaigarajan Parumasivam, Dr

Dr. Thaigarajan Parumasivam holds a Bachelor of Science (Hons) in Microbiology, a Master's in Science in Pharmaceutical Technology from USM, and a PhD in Pharmacy from the University of Sydney, Australia. Presently, he serves as a senior lecturer at the School of Pharmaceutical Sciences, USM.

His research is dedicated to the intersection of microbiology and drug delivery, positioning him uniquely to develop effective and microbiologically sound formulation systems, particularly for pulmonary and brain delivery. His work has been featured in esteemed publications such as the European Journal of Pharmaceutics and Biopharmaceutics, Molecular Pharmaceutics, and Advanced Drug Delivery Reviews.

In recognition of his contributions, Dr. Parumasivam has been honored with the Global Young Scientist Summit in Singapore 2019 and the ASEAN Science Leadership Fellowship 2019. He currently holds the position of president at the Malaysian Society of Pharmaceutical Technology (MSPT) and is an active member of the Young Scientist Network – Academy of Sciences Malaysia (YSN-ASM). Additionally, he is involved in the France-Malaysia Collaboration Programme for Joint Research (MyTIGER 2023).

  • Research Interest

    1. Pulmonary drug delivery
    2. Nasal drug delivery
    3. Microbiology

    Ongoing Research

    1. Pulmonary delivery of phytochemicals for the treatment of tuberculosis and lung cancer
    2. Intranasal delivery of phytochemicals for the treatment of Alzheimer's disease
    3. Graphene materials for Staphylococcal infections
    1. Pulmonary and nasal drug delivery
    2. Microbiology (Tuberculosis and Staphylococcal Infections)
    1. Ramachandran P., Prakash P., Mohtar N., Kumar KS., Parumasivam T. (2023) Review of inhalable nanoparticles for the pulmonary delivery of anti-tuberculosis drugs, Pharmaceutical Development and Technology, 1-31.
    2. Loo CY., Traini D., Young PM., Parumasivam T., Lee WH. (2023) Pulmonary delivery of curcumin and quercetin nanoparticles for lung cancer – Part 1: Aerosol performance characterisation, Journal of Drug Delivery Science and Technology, 82, 104646.
    3. Loo CY., Traini D., Young PM., Parumasivam T., Lee WH. (2023) Pulmonary delivery of curcumin and quercetin nanoparticles for lung cancer – Part 2: Toxicity and endocytosis, Journal of Drug Delivery Science and Technology, 82, 104375.
    4. Raman S., Murugaiyah V., Parumasivam T. (2022) Andrographis paniculata dosage forms and advances in nanoparticulate delivery systems: an overview, Molecules, 27, 6164.
    5. Prakash P., Lee WH., Loo CY., Wong HSJ., Parumasivam T. (2022) Advances in Polyhydroxyalkanoate nanocarriers for effective drug delivery: An overview and challenges, Nanomaterials, 12, 175.
    6. Pulingam T., Parumasivam T., Gazzal AM., Sulaiman AM., Chee JY, Lakshmanan M., Chin CF., Sudesh K. (2022) Antimicrobial resistance: Prevalence, economic burden, mechanisms of resistance and strategies to overcome, European Journal of Pharmaceutical Sciences, 170, 106103.
    7. Pulingam T., Appaturi JN., Parumasivam T., Ahmad A., Sudesh K. (2022). Biomedical applications of polyhydroxyalkanoate in tissue engineering, Polymers, 14, 2141.
    8. Aishah SAR., Wahab HA., Fisol FA., Abdulbaqi IM., Parumasivam T., Mohtar N., Gazzali AM. (2021). Advances in nanocarriers for effective delivery of docetaxel in the treatment of lung cancer: an overview, Cancers, 13, 400
    9. Xin L.Y., Min T.H., Mohd Zin P.N.L., Pulingam T., Appaturi J.N., Parumasivam T. (2021). Antibacterial potential of Malaysian ethnomedicinal plants against methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA), Saudi Biol Sci, In press
    10. Mohtar N., Parumasivam T., Gazzali A.M., Tan C.S., Tan M.L., Othman R., Fazalul Rahiman S.S., Wahab H.A. (2021). Advanced nanoparticle-based drug delivery systems and their cellular evaluation for non-small cell lung cancer treatment, Cancers, 13, 3539.
    11. Abdulbaqi I.M., Assi, A. Yaghmur R.A., Darwis Y., Mohtar N., Parumasivam T., Saqallah F.G., Wahab H.A. (2021). Pulmonary delivery of anticancer drugs via lipid-based nanocarriers for the treatment of lung cancer: an update, Pharmaceuticals, 14, 725.
    12. Mazlun M.H., Sabran S.F., Abdullah Z., Parumasivam T. (2021). A comparative study of antituberculosis activities of Tetracera macrophylla Wall. Ex Hook. f. & Thoms. stem fractions using different chromatographic stationary phases, IOP Conference Series: Earth and Environmental Science, 736, 012036.
    13. Wong K.T., Osman, H., Parumasivam T., Supratman U., Che Omar M.T., Azmi M.N. (2021). Synthesis, characterization and biological evaluation of new 3,5-disubstituted-pyrazoline derivatives as potential anti-Mycobacterium tuberculosis H37Ra compounds. Molecules, 26, 2081.
    1. FAR121 Microbiology for Pharmacy
    2. FAR123 Microbiology for Pharmacy
    3. FAR224 Drug Delivery and Targeting
    4. FAR420 Pharmaceutical Biotechnology
    5. FAR422 Advanced Drug Delivery
    1. Microbiological testing 
    1. Anugerah Kecemerlangan, Majlis Dekan Farmasi (MDF) 2023 kategori Pengajaran dan Pembelajaran
    2. ASEAN Science Leadership Program 2019 fellowship

School of Pharmaceutical Sciences
11800 Universiti Sains Malaysia, Pulau Pinang, Malaysia.
Tel : . 04-653 3812 | Fax: +604-657 0017

  • Last Modified:
    Isnin 11 November 2024, 12:52:24.